Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bladder Cancer

  Free Subscription

Articles published in
Int Urol Nephrol
    June 2024
  1. DAVID J, Pathak RA
    Editorial comment for "Surgeon-administered regional nerve blocks during radical cystectomy: a feasibility study".
    Int Urol Nephrol. 2024;56:1937-1938.
    >> Share

    May 2024
  2. YAN T, Zhou W, Li C
    Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
    Int Urol Nephrol. 2024 May 24. doi: 10.1007/s11255-024-04086.
    >> Share

  3. ZHU W, Wu L, Xie W, Zhang G, et al
    Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis.
    Int Urol Nephrol. 2024;56:1525-1535.
    >> Share

    April 2024
  4. BERNARDINO RM, Wettstein M, Garisto J, Fleshner NE, et al
    Editorial comment to the paper: RE: low cubilin/myeloperoxidase's ratio as a promising biomarker for prognosis of high grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Apr 2. doi: 10.1007/s11255-024-04035.
    >> Share

  5. LI B, Lin Y, Yang Y, Wang Z, et al
    Patients with periodontitis might increase the risk of urologic cancers: a bidirectional two-sample Mendelian randomization study.
    Int Urol Nephrol. 2024;56:1243-1251.
    >> Share

  6. JAKUS D, Solic I, Borovac JA, Situm M, et al
    The influence of the initial clinical presentation of upper tract urothelial carcinoma on histopathological tumor features.
    Int Urol Nephrol. 2024;56:1335-1341.
    >> Share

    March 2024
  7. SILVA MEDEIROS M, Botelho de Carvalho LA, Alves M, Papoila A, et al
    Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
    Int Urol Nephrol. 2024 Mar 26. doi: 10.1007/s11255-024-03971.
    >> Share

  8. ZHAI H, Wang Y, Chen Z, Wang Z, et al
    Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
    Int Urol Nephrol. 2024;56:941-955.
    >> Share

  9. MOEEN AM, Hameed DA, Mostafa MG, Shaban SH, et al
    Lymphadenectomy before and after radical cystectomy: does this affect the radicality? A prospective randomized comparative study.
    Int Urol Nephrol. 2024;56:965-972.
    >> Share

    February 2024
  10. BRISUDA A, Hornak J, Zemlickova B, Hacek J, et al
    Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study.
    Int Urol Nephrol. 2024 Feb 8. doi: 10.1007/s11255-023-03924.
    >> Share

  11. LI Y, Xu H, Lin T, Zhang J, et al
    Preoperative low plasma creatine kinase levels predict worse survival outcomes in bladder cancer after radical cystectomy.
    Int Urol Nephrol. 2024 Feb 5. doi: 10.1007/s11255-024-03957.
    >> Share

  12. KACZMAREK K, Plage H, Furlano K, Hofbauer S, et al
    Loss of Upk1a and Upk1b expression is linked to stage progression in urothelial carcinoma of the bladder.
    Int Urol Nephrol. 2024;56:499-508.
    >> Share

  13. BAHADORI A, Bray G, Rukin N
    Secondary tumours in orthotopic neobladder using isolated gut segment post radical cystectomy for urothelial carcinoma: a systematic review.
    Int Urol Nephrol. 2024;56:519-525.
    >> Share

  14. WANG S, Wei Z, Shu H, Xu Y, et al
    Early diagnosis and prognostic potential of RAC3 in bladder tumor.
    Int Urol Nephrol. 2024;56:475-482.
    >> Share

    January 2024
  15. WU J, Cheng X, Yang H, Xiao S, et al
    Geriatric nutritional risk index as a prognostic factor in elderly patients with non-muscle-invasive bladder cancer: a propensity score-matched study.
    Int Urol Nephrol. 2024 Jan 4. doi: 10.1007/s11255-023-03905.
    >> Share

  16. SAITO T, Matsumoto K, Tanaka N, Fukumoto K, et al
    Prognostic impact of tumor ureteral invasion on recurrence after radical cystectomy.
    Int Urol Nephrol. 2024;56:129-135.
    >> Share

    November 2023
  17. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
    Int Urol Nephrol. 2023 Nov 19. doi: 10.1007/s11255-023-03867.
    >> Share

  18. GERCEK O, Keles I, Saritas TB, Koyuncu B, et al
    Effect of obturator nerve block during transurethral resection of bladder tumors on the disease recurrence, progression and surgery outcomes.
    Int Urol Nephrol. 2023;55:2765-2772.
    >> Share

  19. MIYAKE M, Nishimura N, Nishioka Y, Fujii T, et al
    Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Nov 1. doi: 10.1007/s11255-023-03851.
    >> Share

    October 2023
  20. KOBERLE B, Usanova S, Piee-Staffa A, Heinicke U, et al
    Strong apoptotic response of testis tumor cells following cisplatin treatment.
    Int Urol Nephrol. 2023 Oct 27. doi: 10.1007/s11255-023-03825.
    >> Share

  21. WEI C, Deng C, Dong R, Hou Y, et al
    Multi-omics analysis reveals critical metabolic regulators in bladder cancer.
    Int Urol Nephrol. 2023 Oct 26. doi: 10.1007/s11255-023-03841.
    >> Share

  22. PAZIR Y, Esmeray A, Caglar U, Erbin A, et al
    Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
    Int Urol Nephrol. 2023 Oct 25. doi: 10.1007/s11255-023-03849.
    >> Share

  23. GERCEK O, Ulusoy K, Yazar VM, Topal K, et al
    Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer.
    Int Urol Nephrol. 2023 Oct 17. doi: 10.1007/s11255-023-03829.
    >> Share

  24. KHALIFA SE
    Immunohistochemical expression of CD117/KIT, HER2, and Erbeta in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients.
    Int Urol Nephrol. 2023;55:2473-2481.
    >> Share

    September 2023
  25. KAYAR R, Bastug Y, Tokuc E, Topaktas R, et al
    Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
    >> Share

  26. XIAOQIN Z, Zhouqi L, Huan P, Xinyi F, et al
    Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.
    Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
    >> Share

  27. YOU C, Li Q, Qing L, Li R, et al
    Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
    Int Urol Nephrol. 2023 Sep 2. doi: 10.1007/s11255-023-03765.
    >> Share

  28. OSMAN Y, Elawdy M, Taha DE, Zahran MH, et al
    Bladder perforation as a complication of transurethral resection of bladder tumors: the predictors, management, and its impact in a series of 1570 at a tertiary urology institute.
    Int Urol Nephrol. 2023;55:2161-2167.
    >> Share

  29. WANG IK, Yu TM, Yen TH, Lin CL, et al
    Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.
    Int Urol Nephrol. 2023;55:2267-2274.
    >> Share

    August 2023
  30. ASSEM A, Kassem A, Sherif M, Lotfi A, et al
    Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer.
    Int Urol Nephrol. 2023 Aug 28. doi: 10.1007/s11255-023-03752.
    >> Share

  31. KIM SH, Choi BG, Oh JS, Chun HJ, et al
    Upper tract heparin instillation for maintenance of ureteral stent patency.
    Int Urol Nephrol. 2023;55:1893-1897.
    >> Share

  32. OPPOLZER IA, Riester J, Buttner R, Burger M, et al
    Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
    Int Urol Nephrol. 2023;55:1943-1949.
    >> Share

  33. WANG Z, Yang Z, Qu C, Li J, et al
    Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.
    Int Urol Nephrol. 2023;55:1957-1970.
    >> Share

    July 2023
  34. MOEEN AM, Faragallah MA, Zarzour MA, Elbehairy AA, et al
    Ileal conduit versus single stoma uretero-cutanoustomy after radical cystectomy in patients >/= 75 years; which technique is better? a prospective randomized comparative study.
    Int Urol Nephrol. 2023;55:1719-1726.
    >> Share

    June 2023
  35. KABA M, Pirincci N, Demir M, Kaba S, et al
    The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
    Int Urol Nephrol. 2023 Jun 20. doi: 10.1007/s11255-023-03666.
    >> Share

  36. SLUSARCZYK A, Zapala P, Olszewska-Slusarczyk Z, Radziszewski P, et al
    The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study.
    Int Urol Nephrol. 2023 Jun 6. doi: 10.1007/s11255-023-03655.
    >> Share

  37. YILMAZ H, Cinar NB, Avci IE, Akdas EM, et al
    Evaluation of comprehensive complication index versus Clavien-Dindo classification in prediction of overall survival after radical cystectomy.
    Int Urol Nephrol. 2023;55:1459-1465.
    >> Share

    May 2023
  38. FU W, Liu D, Xiong Y, Liu C, et al
    The comparison between contrast-enhanced ultrasound and contrast-enhanced magnetic resonance imaging in diagnosing bladder urothelial carcinoma.
    Int Urol Nephrol. 2023;55:1073-1079.
    >> Share

    April 2023
  39. NISHIHARA D, Kijima T, Arai K, Kamai T, et al
    Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
    Int Urol Nephrol. 2023;55:867-874.
    >> Share

    March 2023
  40. GRIZZI F, Hegazi MAAA, Taverna G
    Letter to the editor re: "assessing bladder cancer prognosis through circulating tumor cell analysis and Ki-67 measurement".
    Int Urol Nephrol. 2023 Mar 3. doi: 10.1007/s11255-023-03538.
    >> Share

  41. DEWITT-FOY ME, Anele UA, Accioly JPE, Sharpe MG, et al
    Cancer risk in bladder diverticula: a large institutional analysis of risk and management.
    Int Urol Nephrol. 2023;55:541-546.
    >> Share

  42. QIU Y, Zhang X, Dong Z, Zhang Y, et al
    Comparable survival benefits of partial ureterectomy to radical nephroureterectomy in non-metastatic ureter carcinoma: a population-matched study.
    Int Urol Nephrol. 2023;55:579-588.
    >> Share

    February 2023
  43. CANO GARCIA C, Piccinelli ML, Tappero S, Panunzio A, et al
    Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities.
    Int Urol Nephrol. 2023 Feb 23. doi: 10.1007/s11255-023-03517.
    >> Share

    December 2022
  44. DEVLIN CM, Molokwu CN, Wood B, Yuen KK, et al
    Routine urethroscopic surveillance is of limited value after radical cystectomy: a single centre retrospective cohort analysis.
    Int Urol Nephrol. 2022;54:3139-3144.
    >> Share

    November 2022
  45. YAZICI G, Gokmen E, Kose MG, Cetin B, et al
    The use of natural killer cell activity and PPD test in the prediction of results in intravesical BCG treatment of patients with nonmuscle-invasive bladder cancer.
    Int Urol Nephrol. 2022 Nov 22. doi: 10.1007/s11255-022-03414.
    >> Share

  46. LIU J, Ma C, Li X, Li A, et al
    Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients.
    Int Urol Nephrol. 2022 Nov 5. pii: 10.1007/s11255-022-03406.
    >> Share

    September 2022
  47. CATARINO R, Alves L, Pereira D, Costa G, et al
    Neoadjuvant chemotherapy for muscle-invasive bladder cancer: does variant histology matter?
    Int Urol Nephrol. 2022 Sep 5. pii: 10.1007/s11255-022-03358.
    >> Share

    August 2022
  48. CHAKRA MA, Azoulai D, Moussa M, Ismail K, et al
    The prognostic role of pre-cystectomy thrombocytosis in invasive bladder cancer.
    Int Urol Nephrol. 2022 Aug 25. pii: 10.1007/s11255-022-03346.
    >> Share

  49. VAN GINKEL N, Hermans TJN, Meijer D, Boormans JL, et al
    Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
    Int Urol Nephrol. 2022 Aug 23. pii: 10.1007/s11255-022-03339.
    >> Share

  50. XIAO S, Zhan X, Chen T, Wu J, et al
    Prognostic values of distal ureter involvement and survival outcomes in bladder cancer at T1 and T2 stages: a propensity score matching study.
    Int Urol Nephrol. 2022 Aug 13. pii: 10.1007/s11255-022-03260.
    >> Share

  51. REIS LO, Salustiano ACC, Capibaribe DM, Kiehl IGA, et al
    Castration immunoregulates toll-like receptor-4 in male bladder cancer.
    Int Urol Nephrol. 2022 Aug 8. pii: 10.1007/s11255-022-03336.
    >> Share

  52. SAINI S, Pathak RA, Hemal AK
    Robotic nephroureterectomy in the management of upper tract urothelial cancer: inching toward standard of care?
    Int Urol Nephrol. 2022;54:1777-1785.
    >> Share

    July 2022
  53. HE W, Yang J, Gao M, Liu H, et al
    Pelvic reconstruction and lateral prostate capsule sparing techniques improve early continence of robot-assisted radical cystectomy with orthotopic ileal neobladder.
    Int Urol Nephrol. 2022;54:1537-1543.
    >> Share

  54. BASOURAKOS SP, Al Hussein Al Awamlh B, Borregales LD, Abrahimi P, et al
    A comparative population-based analysis of peritoneal carcinomatosis in patients undergoing robotic-assisted and open radical cystectomy.
    Int Urol Nephrol. 2022;54:1513-1519.
    >> Share

  55. ZHU J, Lu Z, Ke M, Cai X, et al
    Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients.
    Int Urol Nephrol. 2022;54:1505-1512.
    >> Share

    June 2022
  56. JAFFER A, Lee M, Khalil O, Raslan M, et al
    The natural history of low-risk non-muscle-invasive bladder cancer: a collaborative multi-centre study.
    Int Urol Nephrol. 2022 Jun 27. pii: 10.1007/s11255-022-03264.
    >> Share

  57. TAKEN K, Aslan R, Eryilmaz R, Alp HH, et al
    Response to Letter to the Editor 'Serum irisin concentration in patients with bladder cancer'.
    Int Urol Nephrol. 2022;54:1247-1248.
    >> Share

    May 2022
  58. ZHUANG W, Xie H, Yu S, Li Y, et al
    Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer.
    Int Urol Nephrol. 2022 May 24. pii: 10.1007/s11255-022-03200.
    >> Share

  59. CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
    Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity.
    Int Urol Nephrol. 2022 May 4. pii: 10.1007/s11255-022-03221.
    >> Share

    April 2022
  60. KAWADA T
    Serum irisin concentration in patients with bladder cancer.
    Int Urol Nephrol. 2022 Apr 1. pii: 10.1007/s11255-022-03199.
    >> Share

    March 2022
  61. ZHAO X, Wang Y, Liang C
    Cigarette smoking and risk of bladder cancer: a dose-response meta-analysis.
    Int Urol Nephrol. 2022 Mar 25. pii: 10.1007/s11255-022-03173.
    >> Share

  62. YORULMAZ EM, Yilmaz Y, Kose O, Akin Y, et al
    Investigation of the causes of BCG refractory in patients treated with intracavitary BCG as secondary treatment in superficial bladder tumors with transurethral resection.
    Int Urol Nephrol. 2022;54:533-540.
    >> Share

    January 2022
  63. REHME C, Fritsch B, Thomas L, Istin S, et al
    Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients.
    Int Urol Nephrol. 2022;54:71-79.
    >> Share

    November 2021
  64. LI J, Cheng B, Xie H, Zhan C, et al
    Bladder cancer biomarker screening based on non-targeted urine metabolomics.
    Int Urol Nephrol. 2021 Nov 30. pii: 10.1007/s11255-021-03080.
    >> Share

  65. TAKEN K, Aslan R, Eryilmaz R, Alp HH, et al
    Serum irisin is a novel biomarker for bladder cancer detection.
    Int Urol Nephrol. 2021 Nov 22. pii: 10.1007/s11255-021-03074.
    >> Share

  66. PARAJULI P, Luitel BR, Pradhan MM, Chapagain S, et al
    Clinicopathological patterns of bladder carcinoma over 1 year: experience from University Hospital of Nepal.
    Int Urol Nephrol. 2021;53:2289-2294.
    >> Share

    September 2021
  67. GHOREIFI A, Basin MF, Ghodoussipour S, Bazargani ST, et al
    Perioperative outcomes of goal-directed versus conventional fluid therapy in radical cystectomy with enhanced recovery protocol.
    Int Urol Nephrol. 2021;53:1827-1833.
    >> Share

    July 2021
  68. SHEA C, Khawaja AR, Sofi K, Nabi G, et al
    Association of metabolic equivalent of task (MET) score in length of stay in hospital following radical cystectomy with urinary diversion: a multi-institutional study.
    Int Urol Nephrol. 2021;53:1305-1310.
    >> Share

    May 2021
  69. CHAN EO, Chan VW, Poon JY, Chan BH, et al
    Clear cell carcinoma of the urinary bladder: a systematic review.
    Int Urol Nephrol. 2021;53:815-824.
    >> Share

    April 2021
  70. SLUSARCZYK A, Garbas K, Zapala P, Zapala L, et al
    Oncological outcomes of high-grade T1 non-muscle-invasive bladder cancer treatment in octogenarians.
    Int Urol Nephrol. 2021 Apr 26. pii: 10.1007/s11255-021-02870.
    >> Share

    March 2021
  71. TAKAMATSU K, Matsumoto K, Kikuchi E, Ogihara K, et al
    Can random bladder biopsies be eliminated after bacillus Calmette-Guerin therapy against carcinoma in situ?
    Int Urol Nephrol. 2021;53:465-469.
    >> Share

    February 2021
  72. KOIE T, Hashimoto Y, Imai A, Yoneyama T, et al
    Long-term chronological changes in urination status of patients who underwent ileal neobladder reconstruction at a single institution.
    Int Urol Nephrol. 2021;53:275-280.
    >> Share

  73. AZEVEDO RM, de Oliveira Carneiro J, da Silva NDF, Athanazio DA, et al
    Bladder venous malformation.
    Int Urol Nephrol. 2021;53:281-282.
    >> Share

    January 2021
  74. FARAJ KS, Navaratnam AK, Eversman S, Elias L, et al
    Use of treatment pathway improves neoadjuvant chemotherapy use in muscle-invasive bladder cancer.
    Int Urol Nephrol. 2021 Jan 3. pii: 10.1007/s11255-020-02752.
    >> Share

  75. YASUI M, Ohta JI, Aoki S, Tajirika H, et al
    Prognosis of patients with T1 bladder cancer after en bloc transurethral resection of bladder tumor stratified by invasion to the level of the muscularis mucosa.
    Int Urol Nephrol. 2021 Jan 2. pii: 10.1007/s11255-020-02772.
    >> Share

    October 2020
  76. WANG Y, Shen W, Yuan X, Akezhouli S, et al
    A perioperative management to reduce rate of urinary tract infection for patient underwent radical cystectomy with ileal conduit diversion.
    Int Urol Nephrol. 2020 Oct 17. pii: 10.1007/s11255-020-02653.
    >> Share

    June 2020
  77. WU YT, Luo HL, Wang HJ, Chen YT, et al
    Gender effect on the oncologic outcomes of upper urinary tract urothelial carcinoma in Taiwan.
    Int Urol Nephrol. 2020;52:1043-1048.
    >> Share

    April 2020
  78. HASSAN AA, Elbendary M, Radwan M, Abo-Farha MO, et al
    Long-term evaluation of modified orthotopic Y-shaped ileal neobladder (Tanta pouch) with left retro-colic chimney.
    Int Urol Nephrol. 2020;52:681-686.
    >> Share

    January 2020
  79. ZHONG H, Shen Y, Yao Z, Chen X, et al
    Long-term outcome of spiral ileal neobladder with orthotopic ureteral reimplantation.
    Int Urol Nephrol. 2020;52:41-49.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016